A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation

Completed · Phase 3

Conditions studied: Head Lice Infestation

In brief

The purpose of the study was to assess the efficacy, safety and tolerability of a single application of abametapir lotion 0.74% w/w compared to a vehicle control, when applied to the scalp and hair for 10 minutes at home.

Key facts

Study ID

NCT02060903

Run by

Dr. Reddy's Laboratories Limited

People needed

379

Starts

2014-02-01

Expected to finish

2014-08-01

Last updated by the study team

2020-09-23

Who can join

Age: 1 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female, aged six months of age or older.
• Is in good general health based on medical history.
• Has active head lice infestation at Screening as determined by a trained evaluator with the exception of the male head of household who may self-assess as being lice-free. Active head lice infestation is defined as at least three live lice for the index subject and at least one live louse for the other household members.
• The subject and/or their caregiver is physically able and willing to apply the Investigational Product at home.
• Belongs to a household with an eligible index subject with active head lice infestation.
• Agrees to an examination for head lice and to all visits and procedures throughout the study.
• Has signed an informed consent and/or assent form.

You may not qualify if…

• Had treatment (over-the-counter ), home remedy or prescription medication) for head lice within 14 days prior to Day 0.
• Intends to use any other form of lice treatment from Day 0 through the Day 14 visit, unless provided as rescue therapy to this Protocol.
• Intends to use a lice comb from the Day 0 through the Day 14 visit unless provided as rescue therapy to this Protocol.
• Intends to cut their hair, use hair dye/bleach or have permanent wave hairstyling from Day 0 through the Day 14 visit.
• Has a household member(s) who is infested with lice but is not willing or not eligible for enrollment.
• Has a condition that, in the opinion of the Investigator, may increase the risk to the subject and/or the interpretation of the data.
• Has visible skin/scalp condition(s) that are not attributable to head lice infestation, such as an erythema score that is >2, blisters, vesicles which, in the opinion of the investigative personnel or Sponsor, will interfere with safety and/or efficacy evaluations.
• Has eczema or atopic dermatitis of skin/scalp.
• Has had a prior reaction to Nix® or products containing permethrin.
• Receiving systemic or topical medication, which in the opinion of the Investigator, may compromise the integrity of the safety and/or efficacy assessments.
• Has received an investigational agent within 30 days prior to Day 0.
• Does not have a known household affiliation with the household members (i.e., does not stay in one household consistently, or sleeps at one place for several nights and then at another place or location).

Where it is running

• Universal Biopharma Reserach INC — Dinuba, California, United States
• Axis Clinical Trials — Los Angeles, California, United States
• LSRN Reserach — West Palm Beach, Florida, United States
• Impact Clinical Trials — Las Vegas, Nevada, United States
• Haber Dermatology — Beachwood, Ohio, United States
• McKenzie Medical Center — McKenzie, Tennessee, United States
• Radiant reserach Inc. — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.